A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamics of HX15001 in Adult Healthy Volunteers.
Latest Information Update: 17 Jun 2025
At a glance
- Drugs HX 15001 (Primary) ; HX 15001 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Helixon Biotechnology
Most Recent Events
- 17 Jun 2025 New trial record